# NCT03066778 (NCT03066778)

> A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03066778
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Small Cell Lung Cancer (SCLC)
- Interventions: Pembrolizumab; Normal saline solution; Carboplatin; Cisplatin; Etoposide
- Enrollment: 453
- Primary outcome: Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
- Primary outcome: Overall Survival (OS)

## Commentary we found

- X threads: 12
- Podcasts: 4
- YouTube: 3

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=nct03066778

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03066778", "email": "<work email>"}; the inbox owner confirms by the emailed link.